Alyson Haslam - Concepedia

Author

Alyson Haslam

University of California, San Francisco ORCID

Also Known As

A Haslam, A. C. Haslam, A. Haslam, Alyson Haslam, Augustus Haslam, Haslam, Alyson

181

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco University Hospital of Geneva Oregon Health & Science University University of Georgia Oklahoma State University Center for Health Sciences

About

Alyson Haslam is an author at University of California, San Francisco specializing in medicine, public health, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	320
2	Public Health	7	7	133
3	Health Sciences	3	3	126
4	Education	1	1	11
5	Clinical Nutrition	1	1	19

Alyson Haslam

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs Alyson Haslam, Vinay Prasad JAMA Network Open	2019	1.4K
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs Alyson Haslam, Jennifer Gill, Vinay Prasad JAMA Network Open	2020	261
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019 Emerson Y. Chen, Alyson Haslam, Vinay Prasad JAMA Internal Medicine	2020	115
Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action Timothée Olivier, Alyson Haslam, Vinay Prasad JAMA Network Open	2021	110
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020 Alyson Haslam, Minki Kim, Vinay Prasad Annals of Oncology Cancer EpidemiologyMedicineUs Cancer PatientsGenome-targeted Oncology DrugsCancer Management	2021	97
Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials Alyson Haslam, Diana Herrera-Perez, Jennifer Gill, JAMA Network Open	2020	89
Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020 Alyson Haslam, Mark P. Lythgoe, Emma Greenstreet Akman, JAMA Network Open	2021	35
Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020 Miloš D. Miljković, Jordan Tuia, Timothée Olivier, JAMA Internal Medicine Epidemiology Of CancerPharmacotherapyUs FoodPreventive MedicineOncology	2022	30
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020 Timothée Olivier, Alyson Haslam, Vinay Prasad BMC Cancer	2023	30
Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity Timothée Olivier, Alyson Haslam, Jordan Tuia, JAMA Network Open	2023	30

Page 1